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Fibrosis is increasingly appreciated as a major player in adipose tissue dysfunction. In rapidly expanding
adipose tissue, pervasive hypoxia leads to an induction of HIF1a that in turn leads to a potent profibrotic tran-
scriptional program. The pathophysiological impact of adipose tissue fibrosis is likely to play an equally
important role on systemic metabolic alterations as fibrotic conditions play in the liver, heart, and kidney.
Here, we discuss recent advances in our understanding of the genesis, modulation, and systemic impact
of excessive extracellular matrix (ECM) accumulation in adipose tissue of both rodents and humans and
the ensuing impact on metabolic dysfunction.Introduction
Obesity is a primary cause of type 2 diabetes mellitus (T2DM),
characterized by diminished or inappropriate insulin secretion,
insulin insensitivity, and additional metabolic disturbances
such as dyslipidemia and impaired liver functions. A key step
during the progression from the lean to the obese state is the
rapid expansion of adipose tissue. Adipocytes can rapidly reach
the diffusional limit of oxygen due to the inability of the neovas-
culature to keep pace with tissue expansion. Hypoxia is there-
fore an early determinant for adipose tissue dysfunction (Sun
et al., 2011). Hypoxic adipose tissue (AT) has unique alterations
that are likely contributors toward the link of obesity with its
comorbidities. Fibrosis is a hallmark of metabolically dysfunc-
tional AT. Adipocytes are surrounded by a network of extracel-
lular matrix proteins that serve as mechanical support and that
respond to different signaling events (Khan et al., 2009). Main-
taining a high degree of flexibility of the ECMallows AT to expand
in a healthy manner, without adverse metabolic consequences.
Over the course of the development of obesity, increased inter-
stitial fibrosis in white adipose tissue (WAT) may decrease ECM
flexibility and reduce the tissue plasticity, which ultimately leads
to adipocyte dysfunction. Of note, abnormal collagen deposi-
tion, a hallmark of fibrosis development in AT, is tightly associ-
ated with tissue inflammation characterized by infiltration of
macrophages and many other immune cells (Sun et al., 2011).
The pathological impact of fibrosis and inflammation on obesity
and obesity-related metabolic disorders has been extensively
investigated in the past several years. Despite many unresolved
questions, studies from our laboratories and others with different
models have elucidated some molecular mechanisms underly-
ing the dysregulation of AT ECM remodeling and its impact on
metabolic dysfunction, both in rodents and in the clinical setting.
The accumulation of fibrosis is the culmination of several patho-
logical processes and can affect different organs, such as the
liver, heart, and kidney (Wynn, 2007). Fibrosis can also be the
result of local inflammation. Fibrosis is usually defined as an
excessive accumulation of ECM components, which can result
from an imbalance between excess synthesis of fibrillar compo-
nents, such as collagens I, III, and VI, and an impairment in470 Cell Metabolism 18, October 1, 2013 ª2013 Elsevier Inc.degradation of these proteins. The generation of ECM com-
ponents is part of a regenerative step, fundamental to the
replacement of dead or injured cells during the repair process,
in response to inflammation. However, if the damage persists,
pivotal cellular actors, such as myofibroblasts, remain activated,
and fibrillar components initially produced to replace the normal
parenchymal tissue can persist and accumulate in the tissue,
giving rise to the characteristic fibrotic appearance. Thus, while
tissue remodeling and ECM synthesis are initially a physiological
response and beneficial for the tissue, excessive accumulation
of fibrosis in the absence of resolution of inflammation can be
highly deleterious for organ tissue homeostasis and function.
Components of Adipose ECM
Since the function of the ECM depends tightly on its molecular
assembly, it is important to know which components are
involved in the formation of adipose ECM. Studies indicate that
fibronectin and collagens are the most abundant proteins of
interstitial fibers and pericellular basement membranes in AT.
Among these components, type I collagens provide the major
ECM framework necessary to sustain the structure and function
of mesenchymal tissues. While this type of collagen has been
considered to be resistant to proteolysis, several matrix metallo-
proteinases (MMPs) have been reported to digest it under certain
circumstances during development or chronic disease progres-
sion (Stamenkovic, 2003). Another major ECM protein in AT is
collagen VI, whose subunits are highly regulated in adipocytes,
both at the gene expression level and at the posttranslational
level. Due to its pivotal contributions to ECM stability, collagen
VI has been extensively studied by our laboratory with different
mouse models (Khan et al., 2009; Park and Scherer, 2012).
Mature collagen VI is composed of three subunits: a1, a2, and
a3. All these subunits are required for stable formation of the
protein. Upon challenging mice that lack collagen VI with either
a high-fat diet or with an ob/ob mutation, we found that these
mice have impaired ECM stability and hence reduced AT
fibrosis. Also, the local and systemic metabolic parameters are
improved, despite an increase in adipocyte size, both in the
context of a high-fat diet challenge or in the background of
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excess of collagen VI is an important determinant of metabolic
dysregulation. Reduced rates of adipocyte necrosis and a
concomitant reduction of macrophage infiltration were also
observed in the absence of collagen VI. These improved meta-
bolic phenotypes can be rationalized with a model in which the
destabilized ECM leads to reduced mechanical stress on the
rapidly expanding adipocytes. Importantly, we recently reported
that the carboxyl-terminal C5 domain of the a3 chain is proteo-
lytically cleaved from the collagen VI (Col6) microfibrils in obese
fat tissue (Park and Scherer, 2012). While the details of this
cleavage event and the participating proteolytic enzymes still
remain to be identified, the cleaved C5 domain that we refer to
as endotrophin effectively augments fibrosis, angiogenesis,
and inflammation through activation of the TGF-b pathway and
recruitment of macrophages and endothelial cells in tumor tis-
sue. As a result, endotrophin is not only a potent contributor to
AT dysfunction in the context of high-fat diets but also contrib-
utes to more effective growth of breast cancer cells that infiltrate
the fatty stroma of themammary gland. In addition, it is intimately
involved in causing enhanced resistance to chemotherapeutic
agents (Park et al., 2013).
The dynamics of fibrosis are tightly regulated byMMPs, a fam-
ily of neutral endopeptidases that cleave collagenous proteins,
thereby enabling remodeling of ECM. Among 28 members in
the MMP superfamily, the membrane type 1 MMP (MT1-MMP,
also known as MMP14) plays an important role in ECM remodel-
ing of AT (Chun et al., 2006). MT1-MMP is required for the
modulation of tight pericellular collagens to allow preadipocytes
to grow out of the stroma. The congenital absence of MT1-MMP
impairs WAT development, thereby causing a lipodystrophic
phenotype in the adult. Several other MMPs, including MMP-3,
-9, -11, -12, -13, -16, and -24, are also highly expressed in AT,
and their levels are modulated under different physiological
conditions. While there are various models of genetic null muta-
tions of MMPs in the mouse leading to obesity or insulin resis-
tance, their specific functions in obese AT remain to be further
elucidated.
Underlying Mechanisms Leading to Excess ECM
Accumulation
The Role of HIF1a
What is the source of this prevailing ECM stress? Evidence from
our and other laboratories suggests that hypoxia is a major initi-
ating factor for ECM induction. We have observed in rodent
models that within just a few days of high-fat diet feeding, a
doubling of the fat cell area can be observed in some fat pads,
rapidly creating a local hypoxic state (Halberg et al., 2009a). As
a result, HIF1a is induced in AT. Unlike its action in tumor tissues,
HIF1a fails to solicit an effective proangiogenic response in AT.
This is the case even if a transgenic cassette is supplied
that drives the expression of a dominant-active HIF1a in AT.
Despite these conditions, HIF1a is still unable to induce an
angiogenic program in adipocytes. Instead, the presence of
HIF1a induces an alternative transcriptional program, mainly
entailing enhanced synthesis of ECM components, leading
eventually to the development of fibrosis. HIF1amay also induce
a change in cellular redox status, which in turn affects enzymes
involved in collagen crosslinking and stabilization, such as lysyloxidase (LOX) and prolyl-4-hydroxylase (Mariman and Wang,
2010).
Recently, we further demonstrated that this fibrotic response
in obese fat pads can effectively be prevented by either the
use of a chemical HIF1a inhibitor (PX-478) or by overexpression
of a dominant-negative HIF1amutant (Sun et al., 2013). Inhibition
of HIF1a is associatedwithmetabolic improvements, even under
a high-fat-diet challenge. These data further highlight the critical
role of HIF1a in increasing the fibrotic response, an integral
aspect of obesity-associated AT dysfunction.
HIF1 proteins regulate the response to oxygen availability at
the transcriptional level in human AT as well (Karpe et al.,
2002). As such, the gene expression of HIF1a is upregulated in
subcutaneous AT of obese subjects (Cancello et al., 2005).
Similar dysfunctional HIF1 signaling as seen in rodents seems
to prevail in human AT (Halberg et al., 2009a; Jiang et al.,
2011; Krishnan et al., 2012). Overall, these observations sug-
gest an important role of the local oxygen supply and con-
sumption for the overall health of AT. Furthermore, they suggest
an involvement of HIF-driven molecular processes aimed at
maintaining tissue homeostasis in human AT (Goossens et al.,
2011).
Other Models of Excessive ECM Accumulation
The functions of ECMproteins and their modifying enzymes (pro-
teinases) in AT have also been investigated in other mouse
models. In db/db mice, a variety of collagens (mainly types I,
IV, and VI) are found to abnormally accumulate in the epididymal
WAT (Liu et al., 2009). On the other hand, genetic ablation of
MT1-MMP causes the formation of a rigid network of collagen
fibrils and impairs the genesis of adipocytes (Chun et al.,
2006). Hypotrophic adipocytes have also been observed in
mice that are null for a glycoprotein called secreted acidic
cysteine-rich glycoprotein (SPARC), which is critically involved
in ECM synthesis. Moreover, the issue of obesity-associated
ECM accumulation has also been addressed pharmacologically.
Further supporting the role of ECM in the pathogenesis of obesity
development, we demonstrated that the effective antidiabetic
actions of PPARg agonists, such as thiazolidinediones, are
mediated at least partially by taking advantage of the potent
antifibrotic actions of PPARg in adipocytes and macrophages
(Khan et al., 2009) through suppression of the transcription of
collagens. All these data from different models highlight that
the excessive accumulation of ECM is a hallmark of ‘‘unhealthy,’’
pathologically challenged fat pad expansion.
Correlations with Other Pathological Features
of Adipose Tissue
Adipocytes that are encapsulated in a tight ECM ‘‘shell’’ lose
their proper functions in fat pads and undergo necrosis at
increased frequency. After cell death, remnant large lipid drop-
lets remain in the tissue for several weeks. Dysfunctional live
adipocytes surrounding the lipid droplets prompt the infiltration
of macrophages, neutrophils, lymphocytes, and mast cells, initi-
ating a local proinflammatory environment. Macrophages in AT
are differentiated into two broad functional subtypes: M1 and
M2macrophages. TheM1 class refers to the classical, activated,
proinflammatory subtype induced by TH1 cytokines, such as
IFN-g, LPS, and TNF-a, ultimately leading to cytotoxicity and
tissue injury; in contrast, M2 is an inactivated subclass of cells
geared for immune suppression. These cells are alternativelyCell Metabolism 18, October 1, 2013 ª2013 Elsevier Inc. 471
Figure 1. Proposed Models for the Sequential Steps Leading to Adipose Tissue Fibrosis and Metabolic Dysfunction
Obese fat pad expansion quickly leads to a hypoxic state. As a result, HIF1a is induced.
(1) A whole set of ‘‘fibrotic response’’ genes, including collagens and their biosynthetic enzymes, such as LOX, are dramatically upregulated under these
conditions. This regulation results in the abnormal development of ECM, leading to local fibrosis, which triggers necrosis of adipocytes. The dead adipocytes then
attract classically activated proinflammatory M1 macrophages, which ultimately lead to inflammation and metabolic dysfunction.
(2) Other models suggest that HIF1amay also directly induce proinflammatory factors, such as IL6 andMIF, which in turn causesM1macrophage infiltration. The
preadipocytes, macrophages, and interactions between these cell types ultimately produce fibrotic components, which eventually cause pathological expansion
of fat pads.
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TGF-b. Lipid droplets in fibrotic AT are surrounded predomi-
nantly by M1 type macrophages. Indeed, M1 macrophages
have been frequently shown to aggregate and form crown-like
structures (CLSs) surrounding the necrotic adipocytes in
advanced stages of tissue dysfunction (Sun et al., 2011)
(Figure 1). In further support of this notion, several reports high-
light significant correlations between collagen VIa3 and chronic
inflammation, based on increased M1 macrophage infiltration
(Pasarica et al., 2009). The phenomenon of reduced macro-
phage infiltration in AT in collagen VI/ mice further highlights
the causal relationship between ECM, adipocyte survival, and
inflammation (Khan et al., 2009).
In addition, inflammation in obese AT caused by hypoxia can
lead to further, more excessive local ECM accumulation
(Figure 1), leading to a feedforward mechanism for ECM synthe-
sis. Hypoxia upregulates key inflammatory genes, including IL-6
and macrophage inflammation factor 1 (MIF1) through HIF1a in-
duction. Low-grade inflammation in obeseWAT can further stim-
ulate accumulation of interstitial fibrosis (Henegar et al., 2008).
In inflamed fat tissue, both adipocytes (mainly preadipocytes)
and infiltrated macrophages express and secrete collagens.
The secreted levels are tightly regulated by crosstalk between
macrophages and preadipocytes under different physiological
and pathological conditions (Keophiphath et al., 2009).
While the strong relationship linking inflammatory processes
to ECM remodeling components is well-established, a causal472 Cell Metabolism 18, October 1, 2013 ª2013 Elsevier Inc.relationship between inflammation and fibrosis in the progress
of the pathophysiology of obesity remains to be defined in
the context of obesity and lipodystrophy. A detailed time
course analysis over 20 days of high-fat-diet feeding showed
that the fibrotic program is induced shortly after high-fat-diet
challenge, while infiltration of macrophages and the associated
inflammation appear much later in the process (Halberg et al.,
2009a). Based on these data and a thorough review of the
literature, we favor a model in which inflammation is becoming
a driving phenomenon only at later stages in the course of
AT dysfunction, in response to a more fibrotic environment
(Figure 1). Regardless of its exact timing of initiation, an ex-
cessive chronic increase of the local inflammatory tone is a
key mediator for the main downstream sequelae of metabolic
dysfunction in AT.
Abnormal fibrosis in AT is also linked directly or indirectly to
many other pathological changes locally, events that eventually
have a systemic impact as well. For example, pathologic accu-
mulation of ECM contributes to an increased level of signaling
via integrins, contributing to the metabolically unfavorable
environment generally observed in fibrotic fat pads; increased
interstitial fibrosis in WAT also disrupts cell-cell communication,
a critical mediator of fat pad expansion in response to caloric
overload. The rigid nature of these fibrotic fat pads prompts
limited physical andmetabolic flexibility, resulting in ectopic lipid
deposition in peripheral tissues, such as the muscle and in the
liver (Savage et al., 2007).
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While excessive local inflammation in AT is related to systemic
insulin resistance at least in rodents, the temporal and mecha-
nistic connections initiating fibrosis prior to inflammation have
not been worked out in detail as of yet. Moreover, while the
obesity-associated infiltration of monocytes and macrophages
into AT has been extensively studied (Sun et al., 2011; Weisberg
et al., 2003), it remains unclear whether this infiltration of immune
cells is strictly secondary to a concomitant necrosis of adipo-
cytes during fat expansion, whether it is the result of an abnormal
profile of chemokine secretion by ECM-laden adipocytes, or
whether it is a combination of the two. Late-stage processes
related to the interaction between AT inflammation and insulin
sensitivity are better understood. Mechanistically, several com-
ponents of inflammatory pathways have been implicated in
reducing insulin sensitivity, such as TNF-a (Hotamisligil et al.,
1993), c-jun N-terminal kinase (Hirosumi et al., 2002), and
various activators of NF-kB (Yuan et al., 2001). Specifically,
TNF-a induces serine phosphorylation of insulin receptor sub-
strate 1 to inhibit insulin signaling pathways, which ultimately
results in insulin resistance (Hotamisligil et al., 1993). Of note,
Toll-like receptor 4 (TLR4), expressed in both macrophages
and adipocytes, is a key player leading to the induction or sup-
pression of genes orchestrating the inflammatory response
(Shi et al., 2006). There are many additional levels at which an
adipocyte can experience cellular stress caused by a more
prominent ECM. For example, as active endocrine cells, adipo-
cytes secrete many factors that play critical roles in systemic
insulin sensitivity. Disturbances within this ‘‘secretory finger-
print’’ of adipocyte-derived factors as a consequence of a
more prominent ECM can lead to a further reduction in beneficial
adipokines, such as adiponectin, with an ensuing secondary
impact on insulin sensitivity (Halberg et al., 2009b).
Cellular Origin of the ECM: Adipocytes versus
Macrophages?
The quantitative contributions of different cell types toward
fibrotic deposits in AT are difficult to establish. It is clear, though,
that there is no single predominant cell type responsible for ECM
synthesis. Oversized adipocytes are the predominant cell type
by mass in hypoxic AT. However, preadipocytes and macro-
phages are central players as well and are likely to outnumber
adipocytes. In vitro studies suggest that preadipocytes in con-
tact with inflammatory cells, such as macrophages, can be the
high-level ‘‘producers’’ of selective ECM molecules, such as
collagen I, tenascin-C, and fibronectin and its receptor a5-integ-
rin, as well as activin A, as seen in WAT from obese individuals
(Keophiphath et al., 2009). Meanwhile, macrophages are found
to be the master ‘‘regulators’’ of fibrosis. They produce soluble
mediators including transforming growth factor b1 (TGF-b1)
and platelet-derived growth factor (PDGF), which directly acti-
vate fibroblasts and control ECM dynamics by regulating the
balance of various MMPs and their inhibitors (Song et al.,
2000). Macrophages also regulate fibrogenesis by releasing
chemokines that attract fibroblasts and other, inflammatory
cells. With their potential to act in both a pro- and antifibrotic
capacity, as well as their ability to regulate the activation of
myofibroblasts, macrophages are fully integrated into all stages
of the fibrotic process. The observation that the level of mast cell
accumulation is associated with collagen accumulation in obeseAT suggests that these cells contribute to adipose remodeling
(Divoux et al., 2012). Whether mast cells promote or degrade
collagens in adipose depots is unknown. Finally, we cannot
exclude the possibility that adipocytes per se could contribute
to the production of fibrosis as illustrated by the intricate relation-
ship between adipocyte and pericellular collagen in obese
adipose parenchyma (Divoux et al., 2010).
Of note in this context are similarities and differences to the
fibrotic response in the liver. The major source for ECM compo-
nents in the liver is the stellate cell. Surprisingly, the stellate cell,
in its quiescent, inactive state, expresses a transcriptional profile
similar to the adipocyte. Both adiponectin and PPARg, two
archetypical adipocyte markers, are important to clamp stellate
cells in their inactive ‘‘adipocyte-like’’ state (Shafiei et al., 2011).
Upon activation by various insults, these stellate cells turn
into myofibroblasts and unleash their full fibrotic program. The
specific cell types involved and the step-wise progression from
a nonfibrotic to a fibrotic state therefore differ significantly
between AT and the liver.
Relationship to Angiogenesis
Angiogenesis plays a critical role in healthy AT expansion (Sun
et al., 2012). Excessive deposition of ECM can affect the angio-
genic properties of AT. In addition to generating enhanced rigid-
ity to the vasculature, the ECM can either promote or inhibit
angiogenesis directly. For example, Collagen IV, a major base-
ment membrane protein of blood vessels, inhibits the initial
sprouting of vessels during angiogenesis. Many other ECMcom-
ponents also play a role in this process. These ECM components
are expected to make the tissue stiffer and less accommodating
for adipocyte expansion and capillary proliferation. As a result,
the capillary density in obese AT is reduced and is accompanied
by larger, dysfunctional vessels. The regulated expression of the
targets of HIF1a, the major transcription factor mediating hypox-
ic responses, remains controversial in obese AT. Some studies in
mice and human models described up- or downregulation of
VEGF during AT expansion, whereas some other groups report
an increase in HIF1a targets, such as thrombospondin-1 and
PAI-1 (Miranda et al., 2010; Voros et al., 2005).
Paradoxically, we found that endotrophin can stimulate angio-
genesis in tumors through recruitment of endothelial precursor
cells, while at the same time having potent profibrotic properties
(Park and Scherer, 2012).
Several studies have suggested an abnormal oxygen supply in
obese AT in humans as well. Adipose tissue blood flow (ATBF) or
the AT oxygen partial pressures have been measured. Using
radioactive xenon, a first report in 1966 demonstrated a reduc-
tion in the radioisotope clearance in obese subcutaneous AT
(Larsen et al., 1966). A study using a polarographic electrode
to measure the subcutaneous oxygen tension has shown that
obese subcutaneous AT is hypoxic (Kabon et al., 2004). In
humans, the ATBF reduction correlates with the state of insulin
sensitivity of the subjects (Jansson et al., 1998). On the other
hand, it was also recently proposed that obese adipose tissue
may be hyperoxic under some conditions and that the aberra-
tions of oxygen delivery are related to anomalies in oxygen
consumption (Goossens et al., 2011). Another recent paper sug-
gests that with increasing BMI there is a global reduction in
oxygen delivery to AT. For a given BMI, there was at least a
5% variation of arterial blood oxygen saturation. However, theCell Metabolism 18, October 1, 2013 ª2013 Elsevier Inc. 473
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Figure 2. Higher Levels of Fibrosis in Obese versus Lean Subjects in Both Subcutaneous and Visceral AT
Morbidly obese subjects withmore fibrosis in their subcutaneous AT lose less fat mass at 3, 6, and 12months post bypass, suggesting that fibrosis could be used
as a good and independent predictor of weight loss after surgical interventions. Arrows indicate pericellular fibrosis. Data are represented as mean ± SEM.
Adapted from data published in Divoux et al. (2010).
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tures in this group of subjects composed of a majority of lean or
at most merely overweight individuals (Hodson et al., 2013).
Furthermore, in these cases, AT structure was not explored in
detail. Unlike in rodents, a direct link between themeasurements
of local AT hypoxia and human AT fibrosis has not been estab-
lished. An indirect link has been proposed by Pasarica et al.,
wherein measures of AT oxygen pressure in lean/overweight
and obese subjects through a direct insertion of a polarographic
Clark electrode negatively correlate with mRNA levels for
collagen VI (Pasarica et al., 2009). Only one study evaluated
macrophage accumulation in AT and liver injury in obese sub-
jects with chronic intermittent hypoxia resulting from chronic
obstructive sleep apnea. Sleep apnea is an independent factor
for insulin resistance and dyslipidemia. Whereas systemic hyp-
oxia was associated with liver fibro-inflammation, it did not
worsen obesity-induced macrophage accumulation in AT de-
pots in over 100 morbidly obese subjects (Aron-Wisnewsky
et al., 2012), though the link with depot fibrosis was not explored
in this study. Future studies will need to establish better potential
links between AT fibrosis accumulation and altered oxygen de-
livery to the AT in human fat.
Structural and Clinical Manifestations of Fibrosis
in Human Adipose Tissue
The fundamental processes leading to fibrosis are similar in
rodent and human fat tissue. In the case of excessive develop-
ment of AT in human obesity, conditions are geared toward a
state favoring fibrosis deposition. A chronic positive energy bal-
ance promoting obesity development induces AT modifications474 Cell Metabolism 18, October 1, 2013 ª2013 Elsevier Inc.with adipocyte hypertrophy and hyperplasia, accumulation of
immune cells, and neovascularization (Rutkowski et al., 2009).
These morphological modifications lead to ECM remodeling
with degradation of the existing ECM and the production of
new ECM components. The discovery that such processes
could be altered in human AT of obese subjects initially stemmed
from the examination of transcriptomic signatures of AT depots
from lean and obese subjects experiencing weight variation.
There is a dysregulation of many ECM components in AT of
obese compared to lean subjects (Henegar et al., 2008; Mutch
et al., 2009). ECM gene networks are tightly associated with in-
flammatory gene networks. Overfeeding experiments in humans
suggest that early changes in ECM genes occur in moderate
weight gain with trends toward collagen deposition and neovas-
cularization in subcutaneous AT (Alligier et al., 2012). Further
immunohistochemistry experiments confirmed that fibrosis
accumulation is a structural hallmark of obese human AT and
highlighted a close spatial relationship between fibrosis and
immune cells accumulation. The quantification of total fibrillar
collagens by picrosirius red staining revealed higher amounts
of ECM in both subcutaneous and visceral AT in obese versus
lean subjects (Figure 2). The amount of collagen accumulation
in these two depots is positively linked, and moribund adipo-
cytes sometimes appear to be trapped in these collagen depots,
as they are negative for a perilipin stain (Divoux et al., 2010).
Whereas large bundles of collagens are observed through the
adipose parenchyma, the accumulation of collagen around the
adipocyte (i.e., ‘‘periadipocyte collagens’’) was particularly char-
acteristic of obesity. Relationships were found between collagen
accumulation and adipocyte size in AT of children and adults.
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AT (Divoux et al., 2010). Collagens also accumulate around AT
vessels (Divoux et al., 2010; Spencer et al., 2011) (Figure 2). A ge-
netic contribution to the development of profibrotic conditions in
obese AT cannot be excluded. GWAs approaches in other
fibrotic-prone tissues, such as liver fibro-inflammation, have
led to the discovery of the PLNA3 variant (Sookoian and Pirola,
2011). However, no current GWAs studies in obesity have pro-
vided convincing evidence that profibrotic genes contribute
(Sandholt et al., 2012). This may be due to phenotyping
employed in these studies, sincemost GWAS efforts have inves-
tigated the genetic contribution of BMI or visceral adiposity in the
cohorts examined, but did not focus on specific AT phenotypes,
such as inflammation and obesity-associated fibrosis.
Clinical Consequences of AT Fibrosis
A causal impact of AT fibrosis accumulation on obesity-related
complications is difficult to evaluate because of the correlative
nature of investigation in human studies. Bioinformatics analyses
of the AT transcriptome have demonstrated a strong positive
correlation between BMI, AT inflammation, and ECM genes in
morbid obesity (Mutch et al., 2009).
The relationship between AT fibrosis and insulin resistance
was documented in a human study in which collagen VI expres-
sion strongly correlated with glucose metabolism impairment
(Pasarica et al., 2009). Those data were further supported by a
more recent study demonstrating an increase in ECM compo-
nents as well as large vessels and capillaries in subcutaneous
AT of obese insulin-resistant subjects compared to a lean control
group (Spencer et al., 2011).
The discovery that the rapid induction of insulin resistance by
acute overfeeding leads to the transcriptional induction of ECM
genes (Tam et al., 2010) suggests that collagen remodeling
and insulin resistance are likely to be linked in human AT as
well. Minimally, the ECM induction could be a result of AT adap-
tation in this specific clinical context.
In morbid obesity, no association between fibrosis accumu-
lation and surrogate markers of insulin resistance was found.
Furthermore, the accumulation of collagen in visceral and sub-
cutaneous depots may have a differential impact on ensuing
complications. The accumulation of fibrosis in visceral depots
was negatively associated with circulating triglycerides. Multi-
variate association showed that serum triglyceride, visceral tis-
sue fibrosis, and adipocyte size were closely related, suggesting
that visceral fibrosis may impact circulating triglycerides levels
by limiting adipocyte size. Obese patients with smaller average
adipocyte cell size manifest a better plasma lipid profile. This is
in agreement with recent observations by Arner and colleagues
showing that women with adipocyte hypertrophy have a more
adverse metabolic profile than women with cellular hyperplasia
at comparable BMI levels (Arner et al., 2010). The generation
of visceral fibrosis could contribute to limit adipocyte expansion,
thus acting as an adaptation mechanism that contributes to
slowing down the negative effect of adipocyte hypertrophy.
However, these relationships could not be established in subcu-
taneous AT.
The mechanisms and kinetics of fibrotic depot accumulations
are unknown and difficult to approach in humans. Clinically,
fibrosis is more abundant in subcutaneous than in visceral
depots where inflammatory cell accumulation is greater, thoughthe nature of the fibrosis in these two depots is quite different.
Interestingly, fibrosis accumulation in subcutaneous AT could
impact weight loss outcomes after bariatric surgery. Patients
undergoing gastric bypass surgery experience a situation lead-
ing to drastic fat mass loss and shrinking adipocytes. Subjects
with more fibrosis in their AT lose less fat mass during the sub-
sequent 12 months postsurgery. While this surgical model is
extremely efficient for rapid fat mass loss in obese patients, there
is significant individual variability in the response to the interven-
tion (Buchwald et al., 2004). Classically, subjects with higher BMI
presurgery lose more weight and fat mass after bariatric surgery
(Flancbaum et al., 1997). Age and metabolic situation also
explain the different weight loss profiles (Campos et al., 2008).
Strikingly, in this study, while the patients had higher BMI, they
had a less favorable fat loss profile. This group also displays
high levels of IL-6. Whether subcutaneous fibrosis could be
used as a good and independent predictor of weight loss in sur-
gical or dietary intervention studies obviously deserves more
attention in larger groups of individuals and with alternative nutri-
tional challenges. Further exploration is also needed to follow the
evolution of fibrotic depots after weight loss and to evaluate the
relationship between fibrosis and AT stiffness (Figure 2).
Therapeutic Interventions: Lifestyle, Surgical, and
Pharmacological
The question of the reversibility of fibrosis is crucial in several
disease states and initiated efforts into new pharmacological
or environmental interventions. Many studies evaluated the
improvements or theworsening of fibrosis in the liver after bariat-
ric surgery. The results are ambiguous. Some groups have
described a slight increase in fibrosis in patients that were
poor responders to bariatric surgery (Mathurin et al., 2006,
2009). Others described a decrease in the ECM gene expres-
sion, supporting the beneficial effects of current surgical proce-
dures (Barker et al., 2006; Dixon et al., 2006; Klein et al., 2006).
With regards to the reversibility of AT fibrosis during weight
loss, the question is not fully resolved. Transcriptomic analysis
and histological evaluation of subcutaneous AT fibrosis on
obese patients prior to bariatric surgery and the same patients
2 years after bariatric surgery have suggested that fibrosis is
not reverted after weight loss (Cancello et al., 2013) and is likely
to take a very long time to reach baseline levels.
Antifibrotic therapies are amajor focus in liver disease. Studies
on anti-TGF-b and activation of PPARg pathways are ongoing.
The process of turnover of AT fibrosis needs to be better under-
stood in order to develop pharmacological interventions to pre-
vent or to inhibit fibrosis in human obesity.
Furthermore, links between lipodystrophy and fibrosis accu-
mulation have been described previously. For example, mice
overexpressing a constitutively active human TGF-b1 developed
a profibrotic phenotype in the liver, kidney, and AT and exhibited
in that case a severe reduction in body fat mass accumulation
with a phenotype reminiscent of lipodystrophy (Clouthier et al.,
1997). In patients with lipodystrophy (due to either genetic
mutations or an anti-HIV therapy), enhanced fibrosis, combined
with small-sized adipocytes, has been described, without any
evidence of an increase in angiogenesis. Whereas a precise
description of the fibrotic depot composition or the kinetics of
fibrosis deposition in the context of these lipodystrophies has
yet to be described, this represents another example of anCell Metabolism 18, October 1, 2013 ª2013 Elsevier Inc. 475
Cell Metabolism
Reviewassociation of fibrosis with pathological conditions (Be´re´ziat
et al., 2011).
Concluding Remarks
Fibrosis is increasingly appreciated as a major hallmark of
dysfunctional AT. Assessed either biochemically as total tissue
hydroxyproline, or histologically as a trichrome or picrosirius red
stain, we find the levels to be routinely inversely associated with
overall metabolic fitness of the fat pad, i.e., the ability of AT to
adapt to changing nutrient conditions. As with many other
tissues, powerful antifibrotic agents that not only prevent the
formation of fibrosis but to some extent have the potential to
reverse it promise to drive significant metabolic improvements,
but are unavailable to date. Furthermore, a better understanding
of what the critical driving forces are for the induction of the
ECM in AT promises to be a fruitful area of diabetes research
in the near future.
ACKNOWLEDGMENTS
The authors thank colleagues in the Touchstone Diabetes Center for help.
Authors were supported by the National Institutes of Health (grants
R01-DK55758, R01-DK099110, and P01DK088761 to P.E.S.) and the Juvenile
Diabetes Research Foundation (JDRF 17-2012-36 to P.E.S.), as well as by the
French National Agency of Research (ANR-Adipofib), Fondation pour la
Recherche Medicale (FRM), and Assistance Publique Hoˆpitaux de Paris,
APHP (Clinical Research Contract, CRC fibrota) to K.C.
REFERENCES
Alligier, M., Meugnier, E., Debard, C., Lambert-Porcheron, S., Chanseaume,
E., Sothier, M., Loizon, E., Hssain, A.A., Brozek, J., Scoazec, J.Y., et al.
(2012). Subcutaneous adipose tissue remodeling during the initial phase of
weight gain induced by overfeeding in humans. J. Clin. Endocrinol. Metab.
97, E183–E192.
Arner, E., Westermark, P.O., Spalding, K.L., Britton, T., Ryde´n, M., Frise´n, J.,
Bernard, S., and Arner, P. (2010). Adipocyte turnover: relevance to human
adipose tissue morphology. Diabetes 59, 105–109.
Aron-Wisnewsky, J., Minville, C., Tordjman, J., Le´vy, P., Bouillot, J.L., Basde-
vant, A., Bedossa, P., Cle´ment, K., and Pe´pin, J.L. (2012). Chronic intermittent
hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese.
J. Hepatol. 56, 225–233.
Barker, K.B., Palekar, N.A., Bowers, S.P., Goldberg, J.E., Pulcini, J.P., and
Harrison, S.A. (2006). Non-alcoholic steatohepatitis: effect of Roux-en-Y
gastric bypass surgery. Am. J. Gastroenterol. 101, 368–373.
Be´re´ziat, V., Cervera, P., Le Dour, C., Verpont, M.C., Dumont, S., Vanty-
ghem, M.C., Capeau, J., and Vigouroux, C.; Lipodystrophy Study Group.
(2011). LMNA mutations induce a non-inflammatory fibrosis and a brown
fat-like dystrophy of enlarged cervical adipose tissue. Am. J. Pathol. 179,
2443–2453.
Buchwald, H., Avidor, Y., Braunwald, E., Jensen, M.D., Pories, W., Fahrbach,
K., and Schoelles, K. (2004). Bariatric surgery: a systematic review and meta-
analysis. JAMA 292, 1724–1737.
Campos, G.M., Rabl, C., Mulligan, K., Posselt, A., Rogers, S.J., Westphalen,
A.C., Lin, F., and Vittinghoff, E. (2008). Factors associated with weight loss
after gastric bypass. Arch. Surg. 143, 877–883, discussion 884.
Cancello, R., Henegar, C., Viguerie, N., Taleb, S., Poitou, C., Rouault, C., Cou-
paye, M., Pelloux, V., Hugol, D., Bouillot, J.L., et al. (2005). Reduction of
macrophage infiltration and chemoattractant gene expression changes in
white adipose tissue of morbidly obese subjects after surgery-induced weight
loss. Diabetes 54, 2277–2286.
Cancello, R., Zulian, A., Gentilini, D., Mencarelli, M., Della Barba, A., Maffei, M.,
Vitti, P., Invitti, C., Liuzzi, A., and Di Blasio, A.M. (2013). Permanence of molec-
ular features of obesity in subcutaneous adipose tissue of ex-obese subjects.
Int. J. Obes. 37, 892. http://dx.doi.org/10.1038/ijo.2013.44.476 Cell Metabolism 18, October 1, 2013 ª2013 Elsevier Inc.Chun, T.H., Hotary, K.B., Sabeh, F., Saltiel, A.R., Allen, E.D., and Weiss, S.J.
(2006). A pericellular collagenase directs the 3-dimensional development of
white adipose tissue. Cell 125, 577–591.
Clouthier, D.E., Comerford, S.A., and Hammer, R.E. (1997). Hepatic fibrosis,
glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCK-TGF-beta1
transgenic mice. J. Clin. Invest. 100, 2697–2713.
Divoux, A., Tordjman, J., Lacasa, D., Veyrie, N., Hugol, D., Aissat, A., Basde-
vant, A., Guerre-Millo, M., Poitou, C., Zucker, J.D., et al. (2010). Fibrosis in
human adipose tissue: composition, distribution, and link with lipid meta-
bolism and fat mass loss. Diabetes 59, 2817–2825.
Divoux, A., Moutel, S., Poitou, C., Lacasa, D., Veyrie, N., Aissat, A., Arock, M.,
Guerre-Millo, M., and Cle´ment, K. (2012). Mast cells in human adipose tissue:
link with morbid obesity, inflammatory status, and diabetes. J. Clin. Endocri-
nol. Metab. 97, E1677–E1685.
Dixon, J.B., Bhathal, P.S., and O’Brien, P.E. (2006). Weight loss and non-alco-
holic fatty liver disease: falls in gamma-glutamyl transferase concentrations
are associated with histologic improvement. Obes. Surg. 16, 1278–1286.
Flancbaum, L., Choban, P.S., Bradley, L.R., and Burge, J.C. (1997). Changes
in measured resting energy expenditure after Roux-en-Y gastric bypass for
clinically severe obesity. Surgery 122, 943–949.
Goossens, G.H., Bizzarri, A., Venteclef, N., Essers, Y., Cleutjens, J.P., Kon-
ings, E., Jocken, J.W., Cajlakovic, M., Ribitsch, V., Cle´ment, K., and Blaak,
E.E. (2011). Increased adipose tissue oxygen tension in obese compared
with lean men is accompanied by insulin resistance, impaired adipose tissue
capillarization, and inflammation. Circulation 124, 67–76.
Halberg, N., Khan, T., Trujillo, M.E., Wernstedt-Asterholm, I., Attie, A.D., Sher-
wani, S., Wang, Z.V., Landskroner-Eiger, S., Dineen, S., Magalang, U.J., et al.
(2009a). Hypoxia-inducible factor 1alpha induces fibrosis and insulin
resistance in white adipose tissue. Mol. Cell. Biol. 29, 4467–4483.
Halberg, N., Schraw, T.D., Wang, Z.V., Kim, J.Y., Yi, J., Hamilton, M.P., Luby-
Phelps, K., and Scherer, P.E. (2009b). Systemic fate of the adipocyte-derived
factor adiponectin. Diabetes 58, 1961–1970.
Henegar, C., Tordjman, J., Achard, V., Lacasa, D., Cremer, I., Guerre-Millo, M.,
Poitou, C., Basdevant, A., Stich, V., Viguerie, N., et al. (2008). Adipose tissue
transcriptomic signature highlights the pathological relevance of extracellular
matrix in human obesity. Genome Biol. 9, R14. http://dx.doi.org/10.1186/
gb-2008-9-1-r14.
Hirosumi, J., Tuncman, G., Chang, L., Go¨rgu¨n, C.Z., Uysal, K.T., Maeda, K.,
Karin, M., and Hotamisligil, G.S. (2002). A central role for JNK in obesity and
insulin resistance. Nature 420, 333–336.
Hodson, L., Humphreys, S.M., Karpe, F., and Frayn, K.N. (2013). Metabolic
signatures of human adipose tissue hypoxia in obesity. Diabetes 62, 1417–
1425.
Hotamisligil, G.S., Shargill, N.S., and Spiegelman, B.M. (1993). Adipose
expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin
resistance. Science 259, 87–91.
Jansson, P.A., Larsson, A., and Lo¨nnroth, P.N. (1998). Relationship between
blood pressure, metabolic variables and blood flow in obese subjects with
or without non-insulin-dependent diabetes mellitus. Eur. J. Clin. Invest. 28,
813–818.
Jiang, C., Qu, A., Matsubara, T., Chanturiya, T., Jou, W., Gavrilova, O., Shah,
Y.M., and Gonzalez, F.J. (2011). Disruption of hypoxia-inducible factor 1 in
adipocytes improves insulin sensitivity and decreases adiposity in high-fat
diet-fed mice. Diabetes 60, 2484–2495.
Kabon, B., Nagele, A., Reddy, D., Eagon, C., Fleshman, J.W., Sessler, D.I., and
Kurz, A. (2004). Obesity decreases perioperative tissue oxygenation. Anesthe-
siology 100, 274–280.
Karpe, F., Fielding, B.A., Ilic, V., Macdonald, I.A., Summers, L.K., and Frayn,
K.N. (2002). Impaired postprandial adipose tissue blood flow response is
related to aspects of insulin sensitivity. Diabetes 51, 2467–2473.
Keophiphath, M., Achard, V., Henegar, C., Rouault, C., Cle´ment, K., and
Lacasa, D. (2009). Macrophage-secreted factors promote a profibrotic pheno-
type in human preadipocytes. Mol. Endocrinol. 23, 11–24.
Cell Metabolism
ReviewKhan, T., Muise, E.S., Iyengar, P.,Wang, Z.V., Chandalia, M., Abate, N., Zhang,
B.B., Bonaldo, P., Chua, S., and Scherer, P.E. (2009). Metabolic dysregulation
and adipose tissue fibrosis: role of collagen VI. Mol. Cell. Biol. 29, 1575–1591.
Klein, S., Mittendorfer, B., Eagon, J.C., Patterson, B., Grant, L., Feirt, N., Seki,
E., Brenner, D., Korenblat, K., and McCrea, J. (2006). Gastric bypass surgery
improves metabolic and hepatic abnormalities associated with nonalcoholic
fatty liver disease. Gastroenterology 130, 1564–1572.
Krishnan, J., Danzer, C., Simka, T., Ukropec, J., Walter, K.M., Kumpf, S., Mirt-
schink, P., Ukropcova, B., Gasperikova, D., Pedrazzini, T., and Krek,W. (2012).
Dietary obesity-associated Hif1a activation in adipocytes restricts fatty acid
oxidation and energy expenditure via suppression of the Sirt2-NAD+ system.
Genes Dev. 26, 259–270.
Larsen, O.A., Lassen, N.A., and Quaade, F. (1966). Blood flow through human
adipose tissue determined with radioactive xenon. Acta Physiol. Scand. 66,
337–345.
Liu, J., Divoux, A., Sun, J., Zhang, J., Cle´ment, K., Glickman, J.N., Sukhova,
G.K., Wolters, P.J., Du, J., Gorgun, C.Z., et al. (2009). Genetic deficiency
and pharmacological stabilization of mast cells reduce diet-induced obesity
and diabetes in mice. Nat. Med. 15, 940–945.
Mariman, E.C., and Wang, P. (2010). Adipocyte extracellular matrix composi-
tion, dynamics and role in obesity. Cell. Mol. Life Sci. 67, 1277–1292.
Mathurin, P., Gonzalez, F., Kerdraon, O., Leteurtre, E., Arnalsteen, L., Holle-
becque, A., Louvet, A., Dharancy, S., Cocq, P., Jany, T., et al. (2006). The
evolution of severe steatosis after bariatric surgery is related to insulin
resistance. Gastroenterology 130, 1617–1624.
Mathurin, P., Hollebecque, A., Arnalsteen, L., Buob, D., Leteurtre, E., Caiazzo,
R., Pigeyre, M., Verkindt, H., Dharancy, S., Louvet, A., et al. (2009). Prospective
study of the long-term effects of bariatric surgery on liver injury in patients
without advanced disease. Gastroenterology 137, 532–540.
Miranda, M., Escote, X., Ceperuelo-Mallafre, V., Megia, A., Caubet, E., Naf, S.,
Gomez, J.M., Gonzalez-Clemente, J.M., Vicente, V., and Vendrell, J. (2010).
Relation between human LPIN1, hypoxia and endoplasmic reticulum stress
genes in subcutaneous and visceral adipose tissue. Int. J. Obes. 34, 679–686.
Mutch, D.M., Tordjman, J., Pelloux, V., Hanczar, B., Henegar, C., Poitou, C.,
Veyrie, N., Zucker, J.D., and Cle´ment, K. (2009). Needle and surgical biopsy
techniques differentially affect adipose tissue gene expression profiles. Am.
J. Clin. Nutr. 89, 51–57.
Park, J., and Scherer, P.E. (2012). Adipocyte-derived endotrophin promotes
malignant tumor progression. J. Clin. Invest. 122, 4243–4256.
Park, J., Morley, T.S., and Scherer, P.E. (2013). Inhibition of endotrophin, a
cleavage product of collagen VI, confers cisplatin sensitivity to tumors.
EMBO Mol. Med. 5, 935–948.
Pasarica, M., Gowronska-Kozak, B., Burk, D., Remedios, I., Hymel, D., Gim-
ble, J., Ravussin, E., Bray, G.A., and Smith, S.R. (2009). Adipose tissue
collagen VI in obesity. J. Clin. Endocrinol. Metab. 94, 5155–5162.
Rutkowski, J.M., Davis, K.E., and Scherer, P.E. (2009). Mechanisms of obesity
and related pathologies: the macro- and microcirculation of adipose tissue.
FEBS J. 276, 5738–5746.Sandholt, C.H., Hansen, T., and Pedersen, O. (2012). Beyond the fourth wave
of genome-wide obesity association studies. Nutr. Diabetes 2, e37. http://dx.
doi.org/10.1038/nutd.2012.9.
Savage, D.B., Petersen, K.F., and Shulman, G.I. (2007). Disordered lipid meta-
bolism and the pathogenesis of insulin resistance. Physiol. Rev. 87, 507–520.
Shafiei, M.S., Shetty, S., Scherer, P.E., and Rockey, D.C. (2011). Adiponectin
regulation of stellate cell activation via PPARg-dependent and -independent
mechanisms. Am. J. Pathol. 178, 2690–2699.
Shi, H., Kokoeva, M.V., Inouye, K., Tzameli, I., Yin, H., and Flier, J.S. (2006).
TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin.
Invest. 116, 3015–3025.
Song, E., Ouyang, N., Ho¨rbelt, M., Antus, B.,Wang,M., and Exton,M.S. (2000).
Influence of alternatively and classically activated macrophages on fibrogenic
activities of human fibroblasts. Cell. Immunol. 204, 19–28.
Sookoian, S., and Pirola, C.J. (2011). Meta-analysis of the influence of I148M
variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on
the susceptibility and histological severity of nonalcoholic fatty liver disease.
Hepatology 53, 1883–1894.
Spencer, M., Unal, R., Zhu, B., Rasouli, N., McGehee, R.E., Jr., Peterson, C.A.,
and Kern, P.A. (2011). Adipose tissue extracellular matrix and vascular abnor-
malities in obesity and insulin resistance. J. Clin. Endocrinol. Metab. 96,
E1990–E1998.
Stamenkovic, I. (2003). Extracellular matrix remodelling: the role of matrix
metalloproteinases. J. Pathol. 200, 448–464.
Sun, K., Kusminski, C.M., and Scherer, P.E. (2011). Adipose tissue remodeling
and obesity. J. Clin. Invest. 121, 2094–2101.
Sun, K., Wernstedt Asterholm, I., Kusminski, C.M., Bueno, A.C., Wang, Z.V.,
Pollard, J.W., Brekken, R.A., and Scherer, P.E. (2012). Dichotomous effects
of VEGF-A on adipose tissue dysfunction. Proc. Natl. Acad. Sci. USA 109,
5874–5879.
Sun, K., Halberg, N., Khan, M., Magalang, U.J., and Scherer, P.E. (2013).
Selective inhibition of hypoxia-inducible factor 1a ameliorates adipose tissue
dysfunction. Mol. Cell. Biol. 33, 904–917.
Tam, C.S., Viardot, A., Cle´ment, K., Tordjman, J., Tonks, K., Greenfield, J.R.,
Campbell, L.V., Samocha-Bonet, D., and Heilbronn, L.K. (2010). Short-term
overfeeding may induce peripheral insulin resistance without altering subcu-
taneous adipose tissue macrophages in humans. Diabetes 59, 2164–2170.
Voros, G., Maquoi, E., Demeulemeester, D., Clerx, N., Collen, D., and Lijnen,
H.R. (2005). Modulation of angiogenesis during adipose tissue development
in murine models of obesity. Endocrinology 146, 4545–4554.
Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L., and
Ferrante, A.W., Jr. (2003). Obesity is associated with macrophage accumula-
tion in adipose tissue. J. Clin. Invest. 112, 1796–1808.
Wynn, T.A. (2007). Common and unique mechanisms regulate fibrosis in
various fibroproliferative diseases. J. Clin. Invest. 117, 524–529.
Yuan, M., Konstantopoulos, N., Lee, J., Hansen, L., Li, Z.W., Karin, M., and
Shoelson, S.E. (2001). Reversal of obesity- and diet-induced insulin resistance
with salicylates or targeted disruption of Ikkbeta. Science 293, 1673–1677.Cell Metabolism 18, October 1, 2013 ª2013 Elsevier Inc. 477
